PJSP HEALTHCARE EXPERT

JSP Pharmaceutical Public Company Limited [JP]

OPPORTUNITY DAY FY 2021

March 11<sup>th</sup> 2022



### **Management Team**



Mr. Sittichai Daengprasert

President

Through **15 years of experience as JP's president**, Mr. Sittichai has laid foundation for the business and grown the company to become one of the leading OEM pharmaceutical manufacturer in Thailand.



#### Ms. Jirada Daengprasert

Executive Vice President of Finance & Accounting

Ms. Jirada has over **14 years of** experience in finance and accounting. She also served as Executive Director of COX Laboratories, a leading pharmaceutical manufacturer, which combined with JP in 2017.

## FY 2021 HIGHLIGHTS









## **Approved Company** for Hemps **Extraction License**



**TV Directs** 

## 175

- Implement **D2C** strategy through TV Directs
- **Enhanced Own**  $\checkmark$ brand, "Wolffia" and "Black Sesame Oil + Rice Bran Oil"
- $\checkmark$ Engaged with TV Directs for marketing management

## .....

- **Revenue from OEM** increased Baht 24.9 million or 10.0% YoY
- **Gross Profit Margin was**  $\checkmark$ 34.2% improved from 31.5% YoY
- Normalized Net Profit  $\checkmark$ **increased** Baht 2.2 million or 7.0% YoY



- Issued new shares 115 Million shared at 7 Baht in October
- Traded for ordinary  $\checkmark$ shares in mai market on 2 November

- Company MOU with  $\checkmark$ **KTDM and WMTA**
- Joined partnership with  $\checkmark$ WMTA for hemp R&D prototype
- $\checkmark$ Secured raw materials from KTDM to product the extract

## Agenda





## JP At a Glance



Becoming the leading company in research, manufacture and distribution of pharmaceuticals and supplements



#### **Innovating Toward the Future**

Partnership with leading education & research institute:



Commercialize innovative research:



Plant-based Protein Supplement



Herbal Remedy from Hemp




6

## **JP Key Differentiation**

One-Stop Service Capability	International Standard Facility 2	Large Versatile License Selection	R&D Capability & Collaboration	Presence in ASEAN Market
<ul> <li>Provides B2B customer with end- to-end service from product design and development to distribution assistance</li> <li>Trusted by major drugstore chain as supplier</li> </ul>	<ul> <li>Received GMP standard for Pharmaceutical, herbal product, and supplement production facility</li> <li>Among a few manufacturer to received PIC/s standard, ISO, and Halal</li> </ul>	<ul> <li>Owned a total of 1,900 licenses for all products</li> <li>Addition options for cosmetic and hemp extraction licenses</li> <li>Allow customer to receive a shorter time-to-market</li> </ul>	<ul> <li>In-house R&amp;D and collaboration with leading research institute</li> <li>Produce unique products with exclusive license that could create competitive advantages</li> </ul>	<ul> <li>Exported in ASEAN: Laos, Cambodia, Myanmar, Philippines, Singapore</li> </ul>


## FY 2021 Operating Revenue Breakdown





## **Revenue Breakdown by Business Line : OEM**








## **Revenue Breakdown by Business Line : Own Brand**



## **Revenue Breakdown by Business Line : Trading**



## Agenda





### **JP Strategic Directions**





Hemp & Cannabis Products Black Sesame Oil + Rice Bran Oil

2022

+50% Sales Growth

Innovative pharmaceuticals and supplements product manufacturer

- Putting **innovation** at the forefront of JP business
- ✓ Launching hemp/cannabis products
- ✓ Leverage own Brand growth



2023

Thailand's leading innovative pharmaceutical and supplement brand

- ✓ Thailand's well-known pharmaceutical and supplement brand
- ✓ Continuous R&D and innovative product launch
- ✓ Expand to animal products
- Recognized revenue from new production facilities fully operational





### 2X Sales Growth

ASEAN's leading company in research, manufacturing and distribution of pharmaceutical and supplement product

2024

 Establish strong presence in Southeast Asia for both own-brand and OEM business line



## **COMPANY STRATEGIES**

#### Innovation for Growth

- Continuous R&D for innovative products
- Current innovation for growth:
  - ✓ Plant-based protein supplement
  - ✓ *Hemp* herbal products
  - ✓ Chewable soft gelatin capsule

#### **2** Elevate Own-Brand Business

- Obtain new product licenses
- Introduce differentiated ownbrand products
- Launch wide-scale marketing to strengthen brand awareness

# 5 .....

#### **Expand to CLMV**

4

- Acquire new licenses in each country
- **Expand distribution** of products through local distributor

#### Capture Opportunity Through Investment

 Invest in small-andmedium-size
 pharmaceutical
 companies with high
 growth potential

#### **Strengthen OEM Business**


- Leverage current strengths and focus on *acquiring new major partner*
- Adding *new innovative products* to enhance customer's choice

### **<u>1. Innovation for Growth:</u> Putting innovation at the forefront of JP business**





- Leveraging innovation as differentiation point to enhance company's competitive advantages
- Partnering with leading education institutes and companies for research and development



for THC isolate

### **<u>2. Elevate Own-Brand Business</u>: Targeting to grow at 200% in 2022** by increasing product portfolio and brand awareness





#### **Benefits**

- Enhance profitability from higher margin of own-brand products
- Propel overall company's growth and utilize existing brand



#### Increase Product Abundance

#### Introduce Differentiated Own-Brand Products



+ Rice Bran Oil

#### Target

 $\checkmark$  For those who are concerned about diabetes.

 $\checkmark$  For those who are concerned about alcohol and blood pressure.

#### **Benefits**

- ✓ Bone density strengthening.
- **Black Sesame Oil** ✓ Relieve pain, inflammation, and take care of knee joints.
  - ✓ Improve sleep quality



In 2023, the company will launch its **own** cannabis products

#### สภาพโอสถั

Introduce more than 4 new products per year under "Suphap Osot"



**Registering soft** *gelatin capsule* and pharmaceutical medicine license



2021

2022

H1

H2

#### **Strengthen Brand Awareness**



55 Public Busses

Billboards

- ✓ Advertise on digital TV
- ✓ Studying brand recognition strategy



✓ Implementing Mass Marketing Campaign




✓ Engage MOU with TV direct to secure sale volumes



- ✓ Distribute consumer approach
  - G Facebook D TikTok
- ✓ Outsourcing call center services

**<u>3. Strengthen OEM Business</u>: Leveraging existing strengths to expand customer base and add new choice for customers</u>** 





## **<u>4. Capture Opportunity Through Investment</u>: Accelerating expansion through inorganic growth opportunity**



#### <u>Benefits</u>

Propel company's growth

Efficiently obtain innovative products, R&D, and attractive brands



#### Investment Purpose



#### **Expand Capacity**

To scale up company max capacity and expand production line



#### **Obtain Brand and Distribution Channel**

To enhance company own brand portfolio and enlarge customer segment



¥=

#### Acquire Pharmaceutical Technology To escalate medicine production technology as

well as improve production efficiency



Mid-Small Size Company Strong Financial Performance Synergy with JP

#### Potential M&A Target along Supply Chain

1

#### **Distribution Channels**

- Company owned distribution channels
- Synergized with existing JP Businesses
- Strengthen JP sale channel



#### **Brand owner**

- Well recognized own-brand products
- Strong revenue stream
- Strong customers based




#### Manufacturer

- Company owned manufacturing plant
- Manufacturer for pharmaceutical products

### **<u>5. Expand CLMV+ Market</u>: Grow further in CLMV+ markets**






## Agenda






## HEALTHCARE EXPERT

## **FY 2021 Financial Performance Highlights**




### **Revenue Breakdown by Business**








## **Strong Profitability: Gross Profit**




## **Strong Profitability: Normalized Profit**





23

## **Statement of Financial Position**




٠

Improved the land value due to the acquisition of new contracts


Retained earnings increased from net profit of the company


## **Key Financial Ratios**






#### **Debt Service Coverage Ratio**





ROE



**D/E Ratio** 


## Agenda





## **2022 OUTLOOK**

"JP expects to deliver performance with 50% growth supported by secured orders from own-brand business"





# **THANK YOU**


Please scan to give us your feedback



# APPENDIX

### **JP Key Milestones**





## **Shareholding and Company Structure**






## 2021 JP Cost Breakdown



#### FY 2021 Breakdown



Note: Revenue including revenue from sale and other income

#### **Full Year Analysis**

In FY 2021 the Company recorded revenue of Baht 429.1 million


- Cost of good sold was Baht 278 million or 64.8% of total revenue
- · Administrative expense, which is the second largest cost was Baht 56.4 million or 13.1% of revenue, mainly due to expenses related to IPO
- Selling expenses was Baht 46.9 million or 10.9% of total revenue, decreased from 2020 mainly due to lower transportation cost
- Interest and tax expense was Bath 18.1 million or 4.2% of revenue, due to the repayment of short-term loan and lower interest payments.
- Although the gross profit for FY2021 has increased, the net profit has declined as a result of the higher expenses, mainly from administrative expenses from IPO activities. The net profit was Baht 29.7 million or 7.0% of revenue for FY 2021
- If the expenses related to IPO was excluded, the Company's normalized profit will be Baht 33.3 million or about 7.8% of revenue

SG&A




#### SG&A AND SG&A TO REVENUE

Million Baht, %



## **Strong Profitability: Normalized EBITDA**





#### 35